MA33470B1 - Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone - Google Patents
Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantroneInfo
- Publication number
- MA33470B1 MA33470B1 MA34586A MA34586A MA33470B1 MA 33470 B1 MA33470 B1 MA 33470B1 MA 34586 A MA34586 A MA 34586A MA 34586 A MA34586 A MA 34586A MA 33470 B1 MA33470 B1 MA 33470B1
- Authority
- MA
- Morocco
- Prior art keywords
- fludrapin
- antibodies against
- consisting mainly
- treatment consisting
- composite treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette invention concerne une polythérapie à base d'un anticorps afucosylé anti-CD20 et de fludarabine et/ou mitoxantrone pour le traitement du cancer, et notamment, la polythérapie des cancers exprimant CD20 à base d'un anticorps afucosylé anti-B-Ly1 humanisé et de fludarabine et/ou mitoxantrone.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09010488 | 2009-08-14 | ||
| EP10162391 | 2010-05-10 | ||
| PCT/EP2010/004940 WO2011018225A1 (fr) | 2009-08-14 | 2010-08-12 | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33470B1 true MA33470B1 (fr) | 2012-07-03 |
Family
ID=42938619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34586A MA33470B1 (fr) | 2009-08-14 | 2010-08-12 | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US20110165152A1 (fr) |
| EP (1) | EP2464380A1 (fr) |
| JP (2) | JP2013501741A (fr) |
| KR (1) | KR20120054069A (fr) |
| CN (1) | CN102470172B (fr) |
| AR (1) | AR077867A1 (fr) |
| AU (1) | AU2010281867A1 (fr) |
| BR (1) | BR112012003066A2 (fr) |
| CA (1) | CA2769595A1 (fr) |
| CL (1) | CL2012000392A1 (fr) |
| CR (1) | CR20120035A (fr) |
| MA (1) | MA33470B1 (fr) |
| MX (1) | MX2012001783A (fr) |
| NZ (1) | NZ597325A (fr) |
| RU (1) | RU2012109451A (fr) |
| SG (1) | SG178322A1 (fr) |
| TW (1) | TWI478724B (fr) |
| WO (1) | WO2011018225A1 (fr) |
| ZA (1) | ZA201201038B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| BR112012003066A2 (pt) * | 2009-08-14 | 2016-11-16 | Roche Glycart Ag | uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado |
| CA2841738C (fr) * | 2011-08-16 | 2022-12-06 | Morphosys Ag | Polytherapie avec anticorps anti-cd19 et analogue de purine |
| SG10201606785UA (en) * | 2011-08-16 | 2016-10-28 | Morphosys Ag | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
| ES2693370T3 (es) * | 2013-05-02 | 2018-12-11 | F. Hoffmann-La Roche Ag | Politerapia de un anticuerpo CD20 afucosilado con un conjugado de anticuerpo CD22-fármaco |
| DE102015220537A1 (de) * | 2015-10-21 | 2016-10-27 | Carl Zeiss Smt Gmbh | Projektionsbelichtungsanlage mit mindestens einem Manipulator |
| CA3045944A1 (fr) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Procedes, dispositifs et systemes de detection du tractus gastro-intestinal |
| CA3054632A1 (fr) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libere a l'aide d'un dispositif ingerable |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| US12227565B2 (en) | 2018-06-20 | 2025-02-18 | Biora Therapeutics, Inc. | Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine |
| CN113348011B (zh) | 2018-11-19 | 2023-04-18 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| CN109827881B (zh) * | 2019-02-26 | 2022-05-31 | 西南石油大学 | 岩石水化作用程度表征方法及系统 |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| WO2023091887A1 (fr) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Méthodes et compositions pour le traitement du lupus érythémateux disséminé (sle) par mosunetuzumab |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5072759A (en) * | 1990-01-22 | 1991-12-17 | Teleflex Incorporated | Reverse stranded conduit |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| AU4079999A (en) | 1998-05-15 | 1999-12-06 | Imclone Systems Incorporated | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| EP2275540B1 (fr) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Procédé de contrôle de l'activité de molécule fonctionnelle immunologique |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| KR101498588B1 (ko) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도 |
| KR20060012622A (ko) * | 2003-05-16 | 2006-02-08 | 하이브리돈, 인코포레이티드 | 화학요법제와 함께 이뮤노머를 사용하는 상승적 암 치료방법 |
| US20050054048A1 (en) | 2003-07-29 | 2005-03-10 | Luigi Grasso | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| AU2004273791A1 (en) | 2003-09-05 | 2005-03-31 | Genentech, Inc. | Antibodies with altered effector functions |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| EP1740946B1 (fr) | 2004-04-20 | 2013-11-06 | Genmab A/S | Anticorps monoclonaux humains diriges contre cd20 |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| US20060188495A1 (en) * | 2005-01-13 | 2006-08-24 | Genentech, Inc. | Treatment method |
| CA2605697A1 (fr) | 2005-04-26 | 2006-11-02 | Bioren, Inc. | Procede de production d'anticorps igg humains a fonctions effectrices renforcees |
| CA2606102C (fr) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine "charniere" |
| AU2006290433B2 (en) | 2005-08-26 | 2012-06-07 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US20090110688A1 (en) * | 2007-10-24 | 2009-04-30 | Georg Fertig | Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor |
| BR112012003066A2 (pt) * | 2009-08-14 | 2016-11-16 | Roche Glycart Ag | uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado |
-
2010
- 2010-08-12 BR BR112012003066A patent/BR112012003066A2/pt not_active IP Right Cessation
- 2010-08-12 MA MA34586A patent/MA33470B1/fr unknown
- 2010-08-12 KR KR1020127006531A patent/KR20120054069A/ko not_active Abandoned
- 2010-08-12 AR ARP100102969A patent/AR077867A1/es unknown
- 2010-08-12 EP EP10744528A patent/EP2464380A1/fr not_active Withdrawn
- 2010-08-12 MX MX2012001783A patent/MX2012001783A/es not_active Application Discontinuation
- 2010-08-12 CN CN201080034452.1A patent/CN102470172B/zh not_active Expired - Fee Related
- 2010-08-12 NZ NZ597325A patent/NZ597325A/en not_active IP Right Cessation
- 2010-08-12 RU RU2012109451/15A patent/RU2012109451A/ru not_active Application Discontinuation
- 2010-08-12 CA CA2769595A patent/CA2769595A1/fr not_active Abandoned
- 2010-08-12 SG SG2012008827A patent/SG178322A1/en unknown
- 2010-08-12 WO PCT/EP2010/004940 patent/WO2011018225A1/fr not_active Ceased
- 2010-08-12 JP JP2012524147A patent/JP2013501741A/ja not_active Ceased
- 2010-08-12 AU AU2010281867A patent/AU2010281867A1/en not_active Abandoned
- 2010-08-13 TW TW099127168A patent/TWI478724B/zh not_active IP Right Cessation
- 2010-08-13 US US12/855,951 patent/US20110165152A1/en not_active Abandoned
-
2012
- 2012-01-19 CR CR20120035A patent/CR20120035A/es unknown
- 2012-02-13 ZA ZA2012/01038A patent/ZA201201038B/en unknown
- 2012-02-14 CL CL2012000392A patent/CL2012000392A1/es unknown
- 2012-06-06 US US13/490,351 patent/US20120263713A1/en not_active Abandoned
-
2013
- 2013-01-18 US US13/745,652 patent/US20140010804A1/en not_active Abandoned
-
2014
- 2014-03-03 JP JP2014040897A patent/JP2014141497A/ja active Pending
- 2014-04-11 US US14/251,308 patent/US20150079073A1/en not_active Abandoned
-
2015
- 2015-06-15 US US14/739,278 patent/US20150274834A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ597325A (en) | 2014-03-28 |
| WO2011018225A1 (fr) | 2011-02-17 |
| KR20120054069A (ko) | 2012-05-29 |
| SG178322A1 (en) | 2012-03-29 |
| MX2012001783A (es) | 2012-05-22 |
| AU2010281867A1 (en) | 2012-02-02 |
| CA2769595A1 (fr) | 2011-02-17 |
| TWI478724B (zh) | 2015-04-01 |
| ZA201201038B (en) | 2012-10-31 |
| US20150079073A1 (en) | 2015-03-19 |
| JP2013501741A (ja) | 2013-01-17 |
| AR077867A1 (es) | 2011-09-28 |
| TW201110981A (en) | 2011-04-01 |
| CL2012000392A1 (es) | 2012-08-17 |
| CR20120035A (es) | 2012-04-18 |
| HK1167339A1 (en) | 2012-11-30 |
| US20140010804A1 (en) | 2014-01-09 |
| JP2014141497A (ja) | 2014-08-07 |
| BR112012003066A2 (pt) | 2016-11-16 |
| US20110165152A1 (en) | 2011-07-07 |
| US20150274834A1 (en) | 2015-10-01 |
| RU2012109451A (ru) | 2013-09-27 |
| CN102470172B (zh) | 2014-09-24 |
| CN102470172A (zh) | 2012-05-23 |
| US20120263713A1 (en) | 2012-10-18 |
| EP2464380A1 (fr) | 2012-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA33469B1 (fr) | Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine | |
| UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
| TW200639182A (en) | Antibody variants and uses thereof | |
| CL2007002667A1 (es) | Uso de trastuzumab para la prevencion o reduccion de la metastasis en un paciente que padece de cancer her2 positivo, que no responde a una monoterapia con trastuzumab ni a una monoterapia con pertuzumab. | |
| EP1844077A4 (fr) | Anticorps dr5 et utilisations de ceux-ci | |
| MA53069B1 (fr) | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer | |
| PA8782201A1 (es) | Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos | |
| MY163521A (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| MA44645B1 (fr) | Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2 | |
| MA40513A (fr) | Conjugués médicament-anticorps anti-cdh6 | |
| GEP20156214B (en) | Monoclonal antibodies | |
| UA92505C2 (ru) | Композиции на основе антитела против cd3 | |
| HN2008000878A (es) | Anticuerpos anti mn y metodos para su utilizacion | |
| EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
| MX2009012949A (es) | Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos. | |
| UA101487C2 (en) | Humanized b-ly1 antibody formulation | |
| MA34059B1 (fr) | Thérapie anti-angiogénique pour le traitement du cancer des ovaires | |
| MX2012001783A (es) | Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona. | |
| MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
| MA31265B1 (fr) | Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20 | |
| MA38161A1 (fr) | Anticorps anti-bmp-6 | |
| TW200603828A (en) | Treatment of disorders | |
| UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
| SG170804A1 (en) | Pseudomonas aeruginosa outer membrane protein pa0427 |